This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions
This study will be the first study investigating the safety, pharmacokinetics (PK), and efficacy of SBS-101 on oral pre-malignant lesions. As such, no clinical data has yet been generated using SBS-101 oral adhesive film.
Leukoplakia, Oral
DRUG: SBS-101|DRUG: Placebo
Percentages of patients with overall response will be summarized by treatment, Overall response is defined as complete or partial response in either clinical or histological outcome without worsening of either., 13 weeks|The percentages of patients reporting any treatment-emergent adverse event (AE) will be tabulated by system organ class and preferred term for each treatment, 13 weeks
Plasma concentrations of isotretinoin will be summarized by treatment using descriptive statistics, 13 weeks
This study will be the first study investigating the safety, pharmacokinetics (PK), and efficacy of SBS-101 on oral pre-malignant lesions. As such, no clinical data has yet been generated using SBS-101 oral adhesive film.